1 rich Libsyn https://www.libsyn.com 90 600 You’ve probably heard the anti-malarial drug hydroxychloroqine is getting a hard look as a potential therapeutic agent in the fight against COVID-19. However, as Harvard Health Publishing senior faculty editor Dr. Rob Shmerling points out, evidence remains weak. On the brighter side, he points to three potential avenues in COVID-19 research where therapies may be put to use while a vaccine remains in development. Living Better, Living Longer https://www.health.harvard.edu/podcast-living-better-living-longer <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/13969661/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="90" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/item/13969661